Efficacy of osimertinib against EGFRvIII+ glioblastoma.

Saved in:
Bibliographic Details
Title: Efficacy of osimertinib against EGFRvIII+ glioblastoma.
Authors: Chagoya G; Department of Neurosurgery, The University of Alabama at Birmingham, Birmingham, AL, USA., Kwatra SG; Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Nanni CW; Departments of Anesthesiology, Duke University Medical Center, Durham, NC, USA., Roberts CM; Departments of Anesthesiology, Duke University Medical Center, Durham, NC, USA., Phillips SM; Tri-Institutional MD-PhD Program, Weill Cornell Medical College, The Rockefeller University, Memorial Sloan Kettering Cancer Institute, New York, NY, USA., Nullmeyergh S; Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA., Gilmore SP; Departments of Anesthesiology, Duke University Medical Center, Durham, NC, USA., Spasojevic I; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA., Corcoran DL; Genomic and Computational Biology, Duke University Medical Center, Durham, NC, USA., Young CC; Departments of Anesthesiology, Duke University Medical Center, Durham, NC, USA., Ballman KV; Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, USA., Ramakrishna R; Department of Surgery, Weill Cornell Medicine, New York, NY, USA., Cross DA; IMED Oncology, Global Medical Affairs, AstraZeneca, Cambridge, UK., Markert JM; Department of Neurosurgery, The University of Alabama at Birmingham, Birmingham, AL, USA., Lim M; Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Gilbert MR; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lesser GJ; Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA., Kwatra MM; Departments of Anesthesiology, Duke University Medical Center, Durham, NC, USA.; Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA.; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Source: Oncotarget [Oncotarget] 2020 Jun 02; Vol. 11 (22), pp. 2074-2082. Date of Electronic Publication: 2020 Jun 02 (Print Publication: 2020).
Publication Type: Journal Article
Journal Info: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1949-2553
DOI:10.18632/oncotarget.27599